| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Mesendogen targets transient receptor potential cation channels, subfamily M, members 6 and 7 (TRPM6 and TRPM7). These are magnesium channels that play a role in magnesium homeostasis. By inhibiting these channels, mesendogen reduces cellular Mg²⁺ uptake. This alteration in magnesium homeostasis promotes mesoderm and definitive endoderm differentiation in stem cells.
|
|---|---|
| ln Vitro |
Human stem cell mesoderm and endoderm secretion is induced by mesendogen (10 μM), which also lowers the levels of neurosecretory markers [1]. In H1 human stem cells, mesendogen (2.5, 10 and 25 μM; SLEEP) dose-dependently lowers intracellular magnesium levels [1].
In vitro, mesendogen is a TRPM6 inhibitor. It enhances the mesoderm and definitive endoderm (DE) differentiations of human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs). Its activity is characterized by its ability to promote differentiation in stem cell cultures. |
| ln Vivo |
In vivo, mesendogen is a research compound used to study magnesium homeostasis in early embryonic cell development. It may be utilized to promote mesoderm and endoderm differentiation in stem cell-based therapies. Its in vivo effects are related to its ability to modulate magnesium homeostasis and promote specific cell lineages.
|
| Enzyme Assay |
In vitro enzyme/receptor binding studies are not applicable to mesendogen, as its target is an ion channel rather than an enzyme or receptor. Its activity is assessed by measuring its effects on TRPM6/TRPM7 channel function using electrophysiological techniques such as patch-clamp recordings or ion flux assays. Magnesium uptake is measured using fluorescent indicators or atomic absorption spectroscopy.
|
| Cell Assay |
Western Blot analysis [1]
Cell Types: H9 hESCs Tested Concentrations: 10 μM Incubation Duration: 7 days Experimental Results: Down-regulated the expression levels of pluripotency markers OCT4 and SOX2. Mesendogen (10 μM; 7 days) inhibits Dorsomorphin-induced neurosecretory activity. In vitro cellular assays for mesendogen involve culturing human embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs) in the presence of serial dilutions of the compound. Differentiation into mesoderm and definitive endoderm is assessed by measuring the expression of lineage-specific markers by qRT-PCR or immunocytochemistry. Cell viability is assessed using standard assays. |
| Animal Protocol |
In vivo animal studies for mesendogen are not typically performed, as it is a research compound used primarily in stem cell biology. If conducted, animal models of stem cell transplantation or developmental biology might be used to assess its effects on differentiation. However, such studies are not well-documented in the literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of mesendogen include a molecular weight of 300.35 and a molecular formula of C₁₇H₁₆N₂O₃. It is a small molecule inhibitor. Detailed pharmacokinetic parameters such as half-life and bioavailability are not extensively documented. It is available as a solid powder for research use.
|
| Toxicity/Toxicokinetics |
Toxicological data for mesendogen are limited, as it is a research compound used in stem cell biology. In cell culture studies, it is generally well-tolerated at concentrations used to promote differentiation. Standard toxicological studies would be required for clinical development. It is intended for research use only and is not approved for human therapeutic use.
|
| References | |
| Additional Infomation |
Mesendogen is a small-molecule inhibitor of the TRPM6/TRPM7 magnesium channels. It is used to promote mesoderm and definitive endoderm differentiation in human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs). It is a valuable tool for studying magnesium homeostasis in early embryonic cell development. It is not approved for human therapeutic use and is available for research purposes.
|
| Molecular Formula |
C18H16CLF3N2OS
|
|---|---|
| Molecular Weight |
400.845652580261
|
| Exact Mass |
400.062
|
| CAS # |
864716-85-8
|
| PubChem CID |
2173015
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
507
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C=CC(C(F)(F)F)=CC=1NC(NC(C1C=CC(=CC=1)C(C)C)=O)=S
|
| InChi Key |
VVFIVYCBLSSVEK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16ClF3N2OS/c1-10(2)11-3-5-12(6-4-11)16(25)24-17(26)23-15-9-13(18(20,21)22)7-8-14(15)19/h3-10H,1-2H3,(H2,23,24,25,26)
|
| Chemical Name |
N-[[2-chloro-5-(trifluoromethyl)phenyl]carbamothioyl]-4-propan-2-ylbenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~249.47 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4947 mL | 12.4735 mL | 24.9470 mL | |
| 5 mM | 0.4989 mL | 2.4947 mL | 4.9894 mL | |
| 10 mM | 0.2495 mL | 1.2473 mL | 2.4947 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
